 The crossover trial design will consist of 2 treatment periods. Each period will include a 50 day wash-in phase Day 0 of the wash-in Day 0 of the treatment period followed by 2 transfusion episodes. An end of study treatment follow-up visit will occur 2-4 weeks after the last per protocol transfusion, prior to the next standard of care transfusion. A final study visit will occur at least 60 days after the last per protocol transfusion. 